IFW Receipt

SCULLY, SCOTT, MURPHY & PRESSER
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW
400 GARDEN CITY PLAZA, SUITE 300
GARDEN CITY, NEW YORK 11530-3319

LEOPOLD PRESSER
FRANK S. DIGIGLIO
PAUL J. ESATTO, JR.
JOHN S. SENSNY
MARK J. COHEN
EDWARD W. GROLZ
STEVEN FISCHMAN
PETER I. BERNSTEIN
THOMAS SPINELLI

ROBERT L. BERNSTEIN
MARVIN BRESSLER
DERMOTT J. COOKE°
RICHARD J. DANYKO
BRADLEY M. MARAZAS
SETH M. WEINFELD
KEITH A. WELTSCH*
YONGZHI YANG°
XIAOCHUN ZHU
°OH BAR ONLY
*MD BAR ONLY
°NC BAR ONLY

YONG LU
LESLIE S. SZIVOS, PH.D.
DAVID J. TORRENTE, J.D.
PATENT AGENTS

DOMINICK A. TUCCIO
TECHNICAL COUNSULTANT

ALLEN R. MORGANSTERN
ALEK P. SZECSY
STEPHEN A. YOUNG
COUNSEL

ZHUANG YUAN
TECHNICAL CONSULTANT

JOHN F. SCULLY
STEPHEN D. MURPHY
KENNETH L. KING
RETIRED

ANTHONY C. SCOTT (1931-1994)
WILLIAM E. McNULTY (1927-1993)

TELEPHONE: (516) 742-4343
FACSIMILE: (516) 742-4366
E-MAIL: Intprop@ssmp.com

March 17, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: USSN: 10/525,928
Alison Mary Rice, et al.
Our Docket: 18679

Dear Sirs:

The Filing Receipt for the above-identified patent application has the Total claims incorrect. It should be:

Total Claim 24

as indicated on the enclosed pages. Please make the corrections and send us a corrected Filing Receipt.

Very truly yours,

Scully, Scott, Murphy & Presser, P.C.

SSM&P/tw
Encl.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/525,928	07/26/2005	1614	2040	12339120 (18679)	8	1	1

CONFIRMATION NO. 2829

CORRECTED FILING RECEIPT

OC000000017725756

23389
SCULLY SCOTT MURPHY & PRESSER, PC
400 GARDEN CITY PLAZA
SUITE 300
GARDEN CITY, NY 11530

Date Mailed: 12/27/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Alison Mary Rice, Queensland, AUSTRALIA;
Derek Hart, Queensland, AUSTRALIA;
Slavica Vuckovic, Queensland, AUSTRALIA;

Assignment For Published Patent Application

The Corporation of the Trustees of the order of the Sisters of Mercy, Queensland, AUSTRALIA

Power of Attorney: The patent practitioners associated with Customer Number **23389**.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU03/01113 08/29/2003

Foreign Applications

AUSTRALIA 2002951082 08/30/2002

If Required, Foreign Filing License Granted: 12/27/2005

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/525,928

Projected Publication Date: 01/05/2006

Non-Publication Request: No

Early Publication Request: No

Title

Generation of dendritic cells from cd34+precursors

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
	PCT/AU2003/001113	12339120 (18679)



24. The following fees are submitted:		Applicant use	Office use
☒ a) Basic national fee	$300.00	$ $300.00	
☒ b) Examination fee	$200.00	$ $200.00	
☒ c) Search fee	$500.00	$ $400.00	
TOTAL OF ABOVE CALCULATIONS =	$1000.00	$ $900.00	

☐ Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is $250 for each additional 50 sheets of paper or fraction thereof.

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole	RATE		
30 - 100 =	-70 /50 =	0	x $250.00	$ $0.00	

Surcharge of $130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).	$ $130.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	33 - 20 =	13	x $50.00	$ $650.00	
Independent claims	1 - 3 =	0	x $200.00	$ $0.00	
MULTIPLE DEPENDENT CLAIMS (if applicable)	☒		+ $360.00	$ $360.00	

TOTAL OF ABOVE CALCULATIONS =	$ $2,040.00	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	$ $0.00	
SUBTOTAL =	$ $2,040.00	
Processing fee of $130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	$ $0.00	
TOTAL NATIONAL FEE =	$ $2,040.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40 per property +	$ $0.00	
TOTAL FEES ENCLOSED =	$ $2,040.00	
Amount to be refunded:		$
Amount to be charged:		$

a. ☒ A check in the amount of $ $2,040.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is

c. ☒ The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-1013/SSMP . A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Correspondence Address
Customer No. 23389

Leopold Presser
SIGNATURE

Leopold Presser
NAME

19,827
REGISTRATION NUMBER

PCTUS1/REV05

PCT/AU2003/001113
Received 26 November 2004

CLAIMS

1. A method for generating a population of myeloid like blood dendritic cells or lymphoid like blood dendritic cells from $CD34^+$ precursor cells said method comprising sorting said $CD34^+$ precursor cells into a population of either myeloid precursor cells characterized by the markers $CD33^+$, $CD7^-$, $CD10^-$ or a population of lymphoid precursor cells characterized by the markers $CD34^{+/-}$, $CD7^+$, $CD10^+$, culturing or expanding the myeloid or lymphoid precursor cells in the combination of Flt3, SCF, IL-3 and/or IL-6 for a time and under conditions sufficient for the myeloid precursor cells to give rise to the myeloid like blood dendritic cells characterized by being $CD11c^+$ and $CD123^-$ and the lymphoid precursor cells to give rise to lymphoid like blood dendritic cells characterized by being $CD11c^-$, $CD123^{hi}$.

2. The method of any one of Claim 1, wherein said $CD34^+$ precursor cells are isolated from a biological sample selected from the group consisting of peripheral blood, PBCMs, stem cells, monocytes, amniotic fluid, chorionic villus, cord blood, and tissue.

3. The method according to any one of Claims 1 or 2, wherein said population of $CD34^+$ precursor cells is differentiated into a specific lineage of dendritic cells selected from the group consisting of myeloid dendritic cells, lymphoid dendritic cells, Langerhans cells, interstitial dendritic cells, Afferent lymph veiled cells, blood dendritic cells and interdigitating cells.

4. The method of Claim 3, wherein said population of $CD34^+$ precursor cell is differentiated into a heterogenous population of dendritic cells.

5. The method of Claim 3, wherein said population of $CD34^+$ precursor cells is differentiated into a substantially homogenous population of dendritic cells.

6. The method of Claim 1, wherein the cytokine is selected from the group consisting of flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF, TNF-α, IL-4, TNF-β, LT-β, IL-2, IL-7, IL-9, IL-15, IL-13, IL-5, IL-1α, IL-1β, IFN-γ, IL-10, IL-17, IL-16, IL-18, HGF, IL-11, MSP, FasL, TRAIL, TRANCE, LIGHT, TWEAK, CD27L, CD30L, CD40L, APRIL, TALL-1, 4-1BBL, OX40L, GITRL, IGF-I, IGF-II, HGF, MSP, FGF-a, FGF-b, FGF-3-19, NGF, BDNF, NTs, Tpo, Epo, Ang1-4, PDGF-AA, PDGF-BB, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, EGF, TGF-α, AR, BTC, HRGs, HB-EGF, SMDF, OB, CT-1, CNTF, OSM, SCF, Flt-3L, M-CSF, MK and PTN or their functional, recombinant or chemical equivalents or homologues thereof.

7. The method of Claim 6, wherein the cytokine is selected from the group consisting flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF, TNF-α or their functional, recombinant or chemical equivalents or homologues thereof.

8. The method of Claim 1, further comprising presenting a peptide on the surface of the dendritic cells, thereby providing a population of antigen presenting dendritic cells.

9. The method of Claim 8, wherein said antigen presenting cell is capable of activating a population of T cells.

10. The method of Claim 9, wherein said population of T cells occurs *in vitro*.

11. The method of Claim 9, wherein said population of T cells occurs *in vivo*.

12. The method of any one of Claims 9 to 11, wherein the T cell is selected from a population of $CD4^+$ T cells and/or $CD8^+$ T cells.

13. The method of Claim 9, wherein said peptide is derived from a polypeptide isolated from a human protein, a pathogen protein or a protein derived from a cancer cell.

14. The method of Claim 13, wherein said pathogen is selected from the group consisting of viruses, bacteria, fungi, ectoparasites, mycoplasms, *Archea*, algae, oomycetes, slime molds, nematodes and amoebeae.

15. The method of Claim 14, wherein said virus is selected from the group consisting of Human Immunodeficiency Virus (HIV), the human papilloma virus, Epstein-Barr virus, the polio virus, the rabies virus, the Ebola virus, the influenza virus, the encephalitis virus, smallpox virus, the rabies virus, the herpes viruses, the sendai virus, the respitory syncytial virus, the othromyxoviruses, the measles viruses, the vesicular stomatitis virus, visna virus and cytomegalovirus.

16. The method of Claim 14, wherein said fungi is selected from the group consisting of *Acremonium* spp., *Aspergillus* spp., *Basidiobolus* spp., *Bipolaris* spp., *Blastomyces dermatidis, Candida* spp., *Cladophialophora carrionii, Coccoidiodes immitis, Conidiobolus* spp., *Cryptococcus* spp., *Curvularia* spp., *Epidermophyton* spp., *Exophiala jeanselmei, Exserohilum* spp., *Fonsecaea compacta, Fonsecaea pedrosoi, Fusarium oxysporum, Fusarium solani, Geotrichum candidum, Histoplasma capsulatum* var. *capsulatum, Histoplasma capsulatum* var. *duboisii, Hortaea werneckii, Lacazia loboi, Lasiodiplodia theobromae, Leptosphaeria senegalensis, Madurella grisea, Madurella mycetomatis, Malassezia furfur, Microsporum* spp., *Neotestudina rosatii, Onychocola canadensis, Paracoccidioides brasiliensis, Phialophora verrucosa, Piedraia hortae, Piedra iahortae, Pityriasis versicolor, Pseudallesheria boydii, Pyrenochaeta romeroi, Rhizopus arrhizus, Scopulariopsis brevicaulis, Scytalidium dimidiatum, Sporothrix schenckii, Trichophyton* spp., *Trichosporon* spp., Zygomcete fungi, *Absidia corymbifera, Rhizomucor pusillus* and *Rhizopus arrhizus*.

17. The method of Claim 14, wherein is said bacteria are selected from the group consisting of *Bacillus anthracis, Bordetella pertussis, Vibrio cholerae, Escherichia coli, Shigella dysenteriae, Clostridium perfringens, Clostridium botulinum, Clostridium tetani, Corynebacterium diphtheriae, Pseudomonas aeruginosa, Bacillus anthracis, Bordetella*

18. The method of Claim 13, wherein said cancer cell is isolated from a cancer cell associated with a cancer selected from the group consisting of ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumours, Breast Cancer, CNS tumours, Carcinoid Tumours, Cervical Cancer, Childhood Brain Tumours, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma-protuberans, Desmoplastic-Small-Round-Cell-Tumour, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumour, Genitourinary Cancers, Germ Cell Tumours, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer, Hereditary Breast Cancer, Histiocytosis, Hodgkin's Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's-Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumour-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage Syndrome, Non-Melanoma Skin Cancer, Non-

Cancer, Oropharynx Cancer, Osteosarcoma, Ostomy Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral-Neuroectodermal-Tumours, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare-cancers-and-associated-disorders, Renal Cell Carcinoma, Retinoblastoma, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumours, Squamous-Cell-Carcinoma-(skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-Cancer-(renal-pelvis-/-ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's-Macroglobulinemia, Wilms' Tumour.

19. The method of Claim 13, wherein the human protein is associated with an autoimmune disease.

20. The method of Claim 19, wherein the autoimmune disease is selected from the group consisting of Addisons Disease, Allergies, Anemia, Ankylosing Spondylitis, Arthritis, Celiac Disease, Crohns Disease, Diabetes, Endometriosis, Fibromyalgia, Graves Disease, Hashimotos Disease, Hypothyroidism, Immune Diseases, Lupus, Lymphoma, Meniere's Disease, Multiple Sclerosis, Oral Diseases, Osteoporosis, Pleurisy, Psoriasis, Reiters Syndrome, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogrens Syndrome, Thrush, Vitiligo, Alopecia Areata, Antiphospholipid Syndrome (APS), Behcet's Disease, Ulcerative Colitis, Goodpasture Syndrome, Graft Versus Host Disease, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myositis, Pemphigus Vulgaris, Primary Biliary Cirrhosis, Rheumatic Fever, Vasculitis and Wegener's Granulomatosis.

21. A method for inducing a protective immune response against an autoimmune disease in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting

22. The method of Claim 19, wherein the autoimmune disease is selected from the group consisting of Addisons Disease, Allergies, Anemia, Ankylosing Spondylitis, Arthritis, Celiac Disease, Crohns Disease, Diabetes, Endometriosis, Fibromyalgia, Graves Disease, Hashimotos Disease, Hypothyroidism, Immune Diseases, Lupus, Lymphoma, Meniere's Disease, Multiple Sclerosis, Oral Diseases, Osteoporosis, Pleurisy, Psoriasis, Reiters Syndrome, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogrens Syndrome, Thrush, Vitiligo, Alopecia Areata, Antiphospholipid Syndrome (APS), Behcet's Disease, Ulcerative Colitis, Goodpasture Syndrome, Graft Versus Host Disease, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myositis, Pemphigus Vulgaris, Primary Biliary Cirrhosis, Rheumatic Fever, Vasculitis and Wegener's Granulomatosis.

23. A method for inducing a protective immune response against cancer in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting dendritic cell generated according to Claim 18.

24. A method for inducing a protective immune response against a pathogen in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting dendritic cell generated according to any one of Claims 13 to 17.